Eleni Xourgia1, Maria G Tektonidou2. 1. First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 2. Department of Propaedeutic Internal Medicine, Medical School, Rheumatology UnitJoint Academic Rheumatology Program - EULAR Centre of Excellence'Laiko' Hospital, National and Kapodistrian University of Athens, 17 Agiou Thoma str, 11527, FirstAthens, Greece. mtektonidou@gmail.com.
Abstract
PURPOSE OF REVIEW: To review the recent available evidence on epidemiology, pathogenesis, clinical phenotypes, and management of antiphospholipid syndrome (APS) and summarize potential future research perspectives. RECENT FINDINGS: Accumulating evidence has further expanded our understanding of the disease, including new data about the incidence and prevalence of APS, novel pathways supporting the role of thrombo-inflammation in APS including platelet, monocyte and endothelial cell activation, pro-inflammatory cytokine and chemokine production, complement activation, neutrophil extracellular trap release, and type I interferon gene expression that could yield to new potential treatment targets, better identification of criteria and non-criteria clinical phenotypes, antiphospholipid antibody profiles and their associations with clinical outcomes, prognostic tools, and treatment strategies based on recent evidence-based recommendations for patients with thrombotic and obstetric APS, with or without systemic lupus erythematosus. Ongoing research efforts and international collaborations enhance our knowledge of this rare and often devastating syndrome and help improve patient care and health outcomes.
PURPOSE OF REVIEW: To review the recent available evidence on epidemiology, pathogenesis, clinical phenotypes, and management of antiphospholipid syndrome (APS) and summarize potential future research perspectives. RECENT FINDINGS: Accumulating evidence has further expanded our understanding of the disease, including new data about the incidence and prevalence of APS, novel pathways supporting the role of thrombo-inflammation in APS including platelet, monocyte and endothelial cell activation, pro-inflammatory cytokine and chemokine production, complement activation, neutrophil extracellular trap release, and type I interferon gene expression that could yield to new potential treatment targets, better identification of criteria and non-criteria clinical phenotypes, antiphospholipid antibody profiles and their associations with clinical outcomes, prognostic tools, and treatment strategies based on recent evidence-based recommendations for patients with thrombotic and obstetric APS, with or without systemic lupus erythematosus. Ongoing research efforts and international collaborations enhance our knowledge of this rare and often devastating syndrome and help improve patient care and health outcomes.
Authors: Michel T Corban; Ali Duarte-Garcia; Robert D McBane; Eric L Matteson; Lilach O Lerman; Amir Lerman Journal: J Am Coll Cardiol Date: 2017-05-09 Impact factor: 24.094
Authors: Ali Duarte-García; Michael M Pham; Cynthia S Crowson; Shreyasee Amin; Kevin G Moder; Rajiv K Pruthi; Kenneth J Warrington; Eric L Matteson Journal: Arthritis Rheumatol Date: 2019-08-01 Impact factor: 10.995
Authors: R Cervera; R Serrano; G J Pons-Estel; L Ceberio-Hualde; Y Shoenfeld; E de Ramón; V Buonaiuto; S Jacobsen; M M Zeher; T Tarr; A Tincani; M Taglietti; G Theodossiades; E Nomikou; M Galeazzi; F Bellisai; P L Meroni; R H W M Derksen; P G D de Groot; M Baleva; M Mosca; S Bombardieri; F Houssiau; J-C Gris; I Quéré; E Hachulla; C Vasconcelos; A Fernández-Nebro; M Haro; Z Amoura; M Miyara; M Tektonidou; G Espinosa; M L Bertolaccini; M A Khamashta Journal: Ann Rheum Dis Date: 2014-01-24 Impact factor: 19.103
Authors: M Krilis; M Qi; Y Ioannou; J Y Zhang; Z Ahmadi; J W H Wong; P G Vlachoyiannopoulos; H M Moutsopoulos; T Koike; A D Sturgess; B H Chong; S A Krilis; B Giannakopoulos Journal: J Autoimmun Date: 2021-06-05 Impact factor: 7.094